• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于光动力疗法的I型光敏剂——中磷取代吡咯宁的合理设计

Rational design of a meso phosphate-substituted pyronin as a type I photosensitizer for photodynamic therapy.

作者信息

Wang Yong, Li Jigai, Zhang Yukun, Nan Yi, Zhou Xin

机构信息

Department of Chemistry, College of Chemistry and Chemical Engineering, Qingdao University, Shandong, China.

Cancer Institute, the Affiliated Hospital of Qingdao University, Shandong, China.

出版信息

Chem Commun (Camb). 2022 Jul 12;58(56):7797-7800. doi: 10.1039/d2cc02124b.

DOI:10.1039/d2cc02124b
PMID:35735141
Abstract

Type I photodynamic therapy (PDT) with less oxygen consumption shows great potential to overcome the malignant hypoxia in solid tumors. Herein, a novel meso phosphate-substituted pyronin PY-P and its nanoparticles (PY-P NPs) were prepared as an efficient type I organic photosensitizer. The data prove that PY-P NPs have outstanding low dark toxicity but high photocytotoxicity under hypoxia (<1% O).

摘要

耗氧量较低的I型光动力疗法(PDT)在克服实体瘤中的恶性缺氧方面具有巨大潜力。在此,制备了一种新型的中磷酸取代吡咯宁PY-P及其纳米颗粒(PY-P NPs)作为一种高效的I型有机光敏剂。数据证明,PY-P NPs具有出色的低暗毒性,但在低氧(<1% O)条件下具有高光细胞毒性。

相似文献

1
Rational design of a meso phosphate-substituted pyronin as a type I photosensitizer for photodynamic therapy.用于光动力疗法的I型光敏剂——中磷取代吡咯宁的合理设计
Chem Commun (Camb). 2022 Jul 12;58(56):7797-7800. doi: 10.1039/d2cc02124b.
2
Perfluorocarbon@Porphyrin Nanoparticles for Tumor Hypoxia Relief to Enhance Photodynamic Therapy against Liver Metastasis of Colon Cancer.用于缓解肿瘤缺氧以增强光动力疗法对抗结肠癌肝转移的全氟化碳@卟啉纳米颗粒
ACS Nano. 2020 Oct 27;14(10):13569-13583. doi: 10.1021/acsnano.0c05617. Epub 2020 Sep 16.
3
Oxygen-producing catalase-based prodrug nanoparticles overcoming resistance in hypoxia-mediated chemo-photodynamic therapy.基于产氧过氧化氢酶的前药纳米颗粒克服缺氧介导的化学-光动力疗法中的耐药性
Acta Biomater. 2020 Aug;112:234-249. doi: 10.1016/j.actbio.2020.05.035. Epub 2020 Jun 2.
4
Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy.全氟碳纳米颗粒可提高光动力疗法中的活性氧水平并抑制肿瘤生长。
Nat Commun. 2015 Nov 3;6:8785. doi: 10.1038/ncomms9785.
5
A Dual-Nanozyme-Catalyzed Cascade Reactor for Enhanced Photodynamic Oncotherapy against Tumor Hypoxia.一种用于增强抗肿瘤缺氧光动力疗法的双纳米酶催化级联反应器
Adv Healthc Mater. 2021 Nov;10(21):e2101049. doi: 10.1002/adhm.202101049. Epub 2021 Sep 8.
6
Rational design of β-carboline as an efficient type I/II photosensitizer to enable hypoxia-tolerant chemo-photodynamic therapy.理性设计β-咔啉作为高效 I/II 型光敏剂以实现耐缺氧的化学-光动力疗法。
Bioorg Chem. 2023 Dec;141:106875. doi: 10.1016/j.bioorg.2023.106875. Epub 2023 Sep 21.
7
New strategy for precise cancer therapy: tumor-specific delivery of mitochondria-targeting photodynamic therapy agents and in situ O-generation in hypoxic tumors.精确癌症治疗的新策略:线粒体靶向光动力治疗剂的肿瘤特异性递送及缺氧肿瘤中的原位氧生成
Biomater Sci. 2020 Jul 21;8(14):3994-4002. doi: 10.1039/d0bm00500b. Epub 2020 Jun 23.
8
Oxygen-Generating Hydrogels Overcome Tumor Hypoxia to Enhance Photodynamic/Gas Synergistic Therapy.产氧水凝胶克服肿瘤乏氧以增强光动力/气体协同治疗。
ACS Appl Mater Interfaces. 2022 Jun 22;14(24):27551-27563. doi: 10.1021/acsami.2c02949. Epub 2022 Jun 10.
9
Manipulate tumor hypoxia for improved photodynamic therapy using nanomaterials.利用纳米材料调控肿瘤缺氧以改善光动力疗法。
Eur J Med Chem. 2023 Feb 5;247:115084. doi: 10.1016/j.ejmech.2022.115084. Epub 2022 Dec 31.
10
Supramolecular micelles as multifunctional theranostic agents for synergistic photodynamic therapy and hypoxia-activated chemotherapy.超分子胶束作为多功能治疗试剂用于协同光动力治疗和缺氧激活化疗。
Acta Biomater. 2021 Sep 1;131:483-492. doi: 10.1016/j.actbio.2021.07.014. Epub 2021 Jul 13.

引用本文的文献

1
Synthesis and properties of novel type I photosensitizer polycyclic amide.新型I型光敏剂多环酰胺的合成与性质
Nanoscale Adv. 2023 Jun 29;5(14):3629-3633. doi: 10.1039/d3na00341h. eCollection 2023 Jul 11.